Grade 3/4 dyspnea and hypokalemia were more frequent with cetuximab monotherapy ( 7.5 % and 5.7 % vs 1.9 % each , respectively ) , and grade 3/4 respiratory failure and disease progression were more frequent with combination ( 5.6 % each vs 1.9 % each ) .